Early increase of plasma homocysteine in sepsis patients with poor outcome

Molecular Medicine

Volumn 16, Issue 11-12, 2010, Pages 498-504

  Ploder, Martin ^a   Kurz, Katharina ^b   Spittler, Andreas ^a   Neurauter, Gabriele ^c   Roth, Erich ^a   Fuchs, Dietmar ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; HOMOCYSTEINE; INTERLEUKIN 6; KYNURENINE; NEOPTERIN; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENTERIC FEEDING; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNE RESPONSE; INFLAMMATION; INJURY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; SHOCK; SURVIVAL;

ADULT; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INTERLEUKIN-6; KYNURENINE; MALE; MIDDLE AGED; NEOPTERIN; SEPSIS; TREATMENT OUTCOME; TRYPTOPHAN; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 78149278761     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00008     Document Type: Article

References (35)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. J. Am. Med. Assoc. 274:1049-57.
2. Welch GN, Loscalzo J. (1998) Homocysteine and atherothrombosis. N. Engl. J. Med. 338:1042-50.
3. Hankey GJ, Eikelboom JW. (1999) Homocysteine and vascular disease. Lancet 354:407-13.
4. KS. (2007) Homocysteine, vitamins, and vascular disease prevention. Am. J. Clin. Nutr. 86:1563S-8S.
5. Ueland PM, Clarke R. (2007) Homocysteine and cardiovascular risk: considering the evidence in the context of study design, folate fortification, and statistical power. Clin. Chem. 53:807-9.
6. Schroecksnadel K, Frick B, Wirleitner B, Schennach H, Fuchs D. (2003) Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin. Exp. Immunol. 134:53-6.
7. Schroecksnadel K, Leblhuber F, Frick B, Wirleitner B, Fuchs D. (2004) Association of hyperhomocysteinemia in Alzheimer disease with elevated neopterin levels. Alzheimer Dis. Assoc. Disord. 18:129-33.
8. Schroecksnadel K, et al. (2003) Moderate hyperhomocysteinaemia and immune activation in patients with rheumatoid arthritis. Clin. Chim. Acta 338:157-64.
9. Bleie Ø, et al. (2007) Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J. Intern. Med. 262:244-53.
10. Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. (2005) Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur. Heart J. 26:457-63.
11. Kaski JC, et al. (2008) Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non- ST-segment elevation acute coronary syndrome. Atherosclerosis 201:176-83.
12. Rifai N, Ridker PM. (2001) High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chem. 47:403-11.
13. Huber C, et al. (1984) Immune response-associated production of neopterin: release from macro - phages primarily under control of interferongamma. J. Exp. Med. 160:310-6.
14. Wirleitner B, et al. (2002) Monocyte-derived dendritic cells release neopterin. J. Leukocyte Biol. 72:1148-53
15. Murr C, Widner B, Wirleitner B, Fuchs D. (2002) Neopterin as a marker for immune system activation. Curr. Drug Metabol. 3:175-87.
16. Zedler S, Faist E. (2006) The impact of endogenous triggers on trauma-associated inflammation. Curr. Opin. Crit. Care 12:595-601.
17. Ploder M, et al. (2009) Accelerated tryptophan degradation in trauma and sepsis patients is related to pro-inflammatory response and to the diminished in vitro response of monocytes. Pteridines 19:54-61.
18. Ploder M, et al. (2009). Tryptophan degradation in multiple trauma patients: survivors versus non-survivors. Clin. Sci. 116:593-598.
19. Strohmaier W, Redl H, Schlag G, Inthorn D. (1987) D-Erythro-neopterin plasma levels in intensive care patients with and without septic complications. Crit. Care Med. 15:757-60.
20. Hensler T, et al. (2003) The clinical value of procalcitonin and neopterin in predicting sepsis and organ failure after major trauma. Shock 20:420-6.
21. Pellegrin K, et al. (2005) Enhanced enzymatic degradation of tryptophan by indoleamine (2,3)- dioxygenase contributes to the tryptophan deficient state seen after major trauma. Shock 23:209-15.
22. Bone RC, Sibbald WJ, Sprung CL (1992) The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101:1481-3.
23. Frick B, et al. (2003) Rapid measurement of total plasma homocysteine by HPLC. Clin. Chim. Acta 331:19-23.
24. Selhub J, et al. (1999) Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann. Intern. Med. 131:331-9.
25. van den Brandhof WE, Haks K, Schouten EG, Verhoef P. (2001) The relation between plasma cysteine, plasma homocysteine and coronary atherosclerosis. Atherosclerosis 2001;157:403-9.
26. Nathan CF, Murray HW, Wiebe ME, Rubin BY. (1983) Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 158:670-89.
27. Connor MJ, Pheasant AE, Blair JA. (1979) The identification of p-acetaminobenzoate as a folate degradation product in rat urine. Biochem. J. 178:795-7.
28. Fuchs D, et al. (2001) Is hyperhomocysteinemia due to oxidative depletion of folate rather than insufficient dietary intake? Clin. Chem. Lab. Med. 39:691-4.
29. Weiss G, et al. (1999) Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin. Exp. Immunol. 116:435-40.
30. Schroecksnadel K, et al. (2003) Hyperhomocysteinemia and immune activation. Clin. Chem. Lab. Med. 41:1438-43.
31. Murr C, et al. (2009 Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis 202:543-9.
32. Murr C, et al. (2007) Inverse association between serum selenium concentrations and parameters of immune activation in patients with cardiac disorders. Clin. Chem. Lab. Med. 45:1224-8.
33. Frick B, Gruber B, Schroecksnadel K, Leblhuber F, Fuchs D. (2006) Homocysteine but not neopterin declines in demented patients on B vitamins. J. Neural. Transm. 113:1815-9.
34. Chen Y, Guillemin GJ. (2009) Kynurenine pathway metabolites in humans: disease and healthy states. Int. J. Tryptophan Res. 2:1-19.
35. Schroecksnadel K, et al. (2008) Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease. Clin. Chem. Lab. Med. 46:648-54.